C Steven Ernest

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Drugs Aging 26:781-90. 2009
  2. ncbi request reprint Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
    C Steven Ernest
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 41:639-54. 2014
  3. ncbi request reprint Simultaneous optimal experimental design for in vitro binding parameter estimation
    C Steven Ernest
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 40:573-85. 2013
  4. ncbi request reprint Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
    C Steven Ernest
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacokinet Pharmacodyn 35:593-618. 2008
  5. ncbi request reprint Methodological comparison of in vitro binding parameter estimation: sequential vs. simultaneous non-linear regression
    C Steven Ernest
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Pharm Res 27:866-77. 2010
  6. ncbi request reprint Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis
    C Steven Ernest
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 49:973-83. 2009
  7. ncbi request reprint Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pharmacotherapy 28:1483-94. 2008
  8. ncbi request reprint Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy
    Jeffrey S Riesmeyer
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 52:789-97. 2012
  9. ncbi request reprint Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects
    Ying G Li
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Platelets 20:316-27. 2009
  10. ncbi request reprint Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:2251-7. 2008

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Drugs Aging 26:781-90. 2009
    ..Prasugrel is a novel antiplatelet agent approved for the treatment of ACS patients undergoing percutaneous coronary intervention, and will be used in this population...
  2. ncbi request reprint Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
    C Steven Ernest
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 41:639-54. 2014
    ....
  3. ncbi request reprint Simultaneous optimal experimental design for in vitro binding parameter estimation
    C Steven Ernest
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 40:573-85. 2013
    ....
  4. ncbi request reprint Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
    C Steven Ernest
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacokinet Pharmacodyn 35:593-618. 2008
    ..The greater PD response with prasugrel compared with clopidogrel was accounted for by greater conversion of dose to active metabolite...
  5. ncbi request reprint Methodological comparison of in vitro binding parameter estimation: sequential vs. simultaneous non-linear regression
    C Steven Ernest
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Pharm Res 27:866-77. 2010
    ..Analysis of simulated data was compared using sequential (NLR) and simultaneous non-linear regression (SNLR) to evaluate precision and accuracy of ligand binding parameter estimation...
  6. ncbi request reprint Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis
    C Steven Ernest
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 49:973-83. 2009
    ..Predicted Pras-AM concentrations in TRITON-TIMI 38 were comparable with historical data...
  7. ncbi request reprint Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pharmacotherapy 28:1483-94. 2008
    ..To investigate the potential effect of atorvastatin 80 mg/day on the pharmacokinetics and pharmacodynamics of the thienopyridines prasugrel and clopidogrel...
  8. ncbi request reprint Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy
    Jeffrey S Riesmeyer
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 52:789-97. 2012
    ....
  9. ncbi request reprint Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects
    Ying G Li
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Platelets 20:316-27. 2009
    ..Gender, race, body weight, and age were identified as statistically significant covariates impacting platelet inhibition...
  10. ncbi request reprint Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:2251-7. 2008
    ..This study evaluated the influence of ranitidine coadministration on the pharmacokinetics and pharmacodynamics of the respective active metabolite of prasugrel and clopidogrel...
  11. ncbi request reprint Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 51:321-32. 2011
    ..These results characterize prasugrel's PK across a range of studies and highlight body weight as the most influential covariate on prasugrel AM exposure, with implications for prasugrel maintenance dosing in clinical practice...
  12. ncbi request reprint Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:53-9. 2008
    ..These results are consistent with patients receiving prasugrel not requiring dose adjustments when treated with drugs primarily metabolized by CYP2B6...
  13. ncbi request reprint Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38
    Rebecca E Wrishko
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 49:984-98. 2009
    ..1%) was 30% (90% confidence interval [CI] 1.16-1.45) higher than exposure in patients > or =60 kg. Mean Pras-AM exposures for patients > or =75 years (10.5%) were 19% (90% CI: 1.11-1.28) higher compared with patients <75 years...
  14. ncbi request reprint Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
    Christopher D Payne
    Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
    J Cardiovasc Pharmacol 50:555-62. 2007
    ..In conclusion, greater exposure to prasugrel's active metabolite results in faster onset, higher levels, and less variability of platelet inhibition compared with high-dose clopidogrel in healthy subjects...